John Kuhn received his BS degree in Pharmacy (1972) and PharmD (1977) from the UT, College of Pharmacy. He completed a residency in Pediatric/Adult Oncology. Dr. Kuhn, Professor of Translational Oncology, is a member of the IVY Foundation Early Phase Clinical Trials Consortium using molecular profiling to guide individualized treatment of adults with glioblastoma. Dr. Kuhn co-developed the Osteoport. This device spurred the development of EZ-IO, which changed emergency medicine practices for both adults and children. He has authored over 400 publications, abstracts and book chapters. He has been acting editor for the journal of Investigational New Drugs (IND). Dr. Kuhn is the recipient of a wide-ranging array of awards and honors, most notable, HOPA (2006) named their annual Keynote Lecture in his name. He is an ACCP fellow. He was Board Certified in Oncology Pharmacy from 2000-13. Dr. Kuhn served as Acting President/Past President of HOPA from 2004-2006. The most significant part of his career is having a part in the education and training of outstanding Oncology/Hematology Pharmacy residents and fellows.